Parenterally administered cladribine (2-chloro-2'-deoxyadenosine) has demonstrated promising efficacy and safety in clinical trials in patients with multiple sclerosis (MS). An oral formulation of this small molecule would be an attractive option for patients. Here, we describe the chemical characte
Characterisation of an inclusion complex between cladribine and 2-hydroxypropyl-β-cyclodextrin
✍ Scribed by Van Axel Castelli, Valeria (author);Trivieri, Giovanni (author);Zucchelli, Ilaria (author);Brambilla, Luigi (author);Barbuzzi, Tony (author);Castiglioni, Chiara (author);Paci, Maurizio (author);Zerbi, Giuseppe (author);Zanol, Margherita (author)
- Publisher
- John Wiley and Sons Inc.
- Year
- 2008
- Tongue
- English
- Weight
- 186 KB
- Volume
- 97
- Category
- Article
- ISSN
- 0022-3549
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
This work was aimed at investigating the feasibility of fluid-bed coating as a new method to prepare cyclodextrin inclusion complex. The inclusion complex of the model drug piroxicam (PIX) and 2-hydroxypropyl-b-cyclodextrin (HPCD) in aqueous ethanol solution was sprayed and deposited onto the surfac
## Abstract The interaction between doxepin, a member of the tricyclic antidepressant (TCA) class of drugs, with β‐cyclodextrin (β‐CD) was investigated using NMR. Several TCAs have been reported to form a complex with β‐CD having 1:1 stoichiometry. Previous results from UV‐visible spectroscopy, flu